

16<sup>th</sup> November 2021

Company Name	Immuno-Biological Laboratories Co., Ltd. (Code Number : 4570)	
Head office Address	1091-1 Naka Aza-Higashida, Fujioka-Shi, Gunma 375-0005, JAPAN	
President	President	Tsutomu Seito
Contact	Board Director	Masato Nakagawa
	Head of IBL group businesses	
TEL	0274-22-2889 (Main)	
URL	<a href="https://www.ibl-japan.co.jp">https://www.ibl-japan.co.jp</a>	

## Business Development of Neosilk®-Human Type Collagen I in European market


### 1. Outline

Neosilk®-Human Type Collagen I which was developed using by our transgenic silkworm technology has been used as cosmetic materials in European market. In addition, the following medical devices which contained Neosilk®-Human Type Collagen I have been released by 303 Pharma (Country: Italy, CEO: Ms. Liliana Abrami and Mr. Marco Benedetti) in the market.

- ① Medical Device Class III – Injectable product for Face, Neck, Decollete (Aesthetic)
- ② Medical Device Class III – Tissue regeneration
- ③ Medical Device Class I – Care Mousse for inflammatory conditions
- ④ Medical Device Class III – viscosupplementation (Injectable drug)
- ⑤ Health Care Products for Animals - Adjuvant corneal treatment (Eye drug) , adjuvant treatment of stomatitis (Buccal gel)

Note: 303 Pharma has registered above medical device products in European market while our product Neosilk®-Human Type Collagen I has been exported and distributed as cosmetic raw materials.

### 2. Relationship





Poly Neo GmbH (Country : Germany, CEO: Mr. Eduard Albrecht)

<https://www.polyneo.eu>

PolyNeo is an appointed distributor who is responsible for sales and marketing of frais vent series produced by Neosilk Cosmetics Co., Ltd. and cosmetics material, Neosilk®-Human Type Collagen I especially in Europe and worldwide (except China).

303 Pharma S.R.L. (Country : Italy, CEO: Ms. Liliana Abrami and Mr. Marco Benedetti)

<http://303pharma.com/>

303 Parma is an expert with profound experience and network in the development, sales, and marketing of cosmetic and medical products. PolyNeo GmbH works exclusively in Italian market with 303 Pharma on Neosilk®-Human Type Collagen I based products for the application of cosmetic and regenerative medical products. Recently, 303 Parma and PolyNeo have agreed to build up a strategic partnership to provide customers worldwide with innovative product concepts and finished formulations based on Neosilk®-Human Type Collagen I. As a result of their great effort, they have released medical classified products (I, III) with regenerative effect, containing Neosilk®-Human Type Collagen I.

### **3. Foreseeing**

The impact of this release on financial results of IBL group in 2021 (end of March 2022) is considered as a minor impact, however, the impact on a mid-term management plan has been currently assessed. Any information which must be released after this press release will be announced in timely manner.

END